The EHDS, an initiative that would be introduced under EU-wide regulation, was first proposed by the European Commission in May 2022.

Its key purpose is to enable the secondary use of anonymized or pseudo-anonymized patient health data for purposes including scientific research and health policy development.

The EHDS could benefit the pharmaceutical industry by permitting researchers to access data collected from patients across the EU for use in certain R&D activities and other purposes, as specified under Article 34 of the draft text.

Although companies could benefit from access to more patient data, they would also be required to share certain types of health data such as that collected during clinical trials. (Also see "EU Health Data Project: More Use Of Real-World Evidence In Price Negotiations" - Pink Sheet, 10 May, 2022.).

EFPIA Calls For Active Inclusion Of Pharma Industry In Roll Out Of European Health Data Space

More from Europe

More from Geography